BMJ open

Intervention for control of hypertension in Catalonia, Spain (INCOTECA Project): results of the multicentric non-randomised quasi-experimental controlled intervention study

Journal:	*BMJ Open*
Manuscript ID:	bmjopen-2011-000507
Article Type:	Research
Date Submitted by the Author:	14-Nov-2011
Complete List of Authors:	Vallès-Fernández, Roser; Primary Care Service Cerdanyola-Ripollet. Catalan Institute of Health, Pharmacy Rodriguez-Blanco, Teresa; IDIAP Jordi Gol FoundationIDIAP Jordi Gol Foundation, Department of Epidemiology and Biostatistics Mengual-Martínez, Lucas; Primary Care Team Badia del vallès Rosell-Murphy, Magdalena; IDIAP Jordi Gol FoundationIDIAP Jordi Gol Foundation, Department of Epidemiology and Biostatistics Prieto-De Lamo, Gemma; IDIAP Jordi Gol FoundationIDIAP Jordi Gol Foundation, Department of Epidemiology and Biostatistics Martínez-Frutos, Fina; Primary Care Team Canaletets-Fontetes Mimoso-Moreno, Sonia; Primary Care Team Canaletets-Fontetes Bellerino-Serrano, Eva; Primary Care Team Ripollet Álvarez-Lázaro, Alícia; Primary Care Team Ripollet Franzi-Sisó, Alícia; Primary Care Service Sabadell-Rubí-St. Cugat-Terrassa Martínez-Vindel, Juan Carlos; Primary Care Team Barberà Alonso-Ortega, Mª Socorro; Primary Care Team Barberà Olmedo-Muñoz, Imma; Primary Care Team Serraparera Bonet-Simó, Josep Mª; Primary Care Service Cerdanyola-Ripollet
Primary Subject Heading:	General practice & Family practice
Secondary Subject Heading:	Public health, Qualitative research, Cardiovascular medicine
Keywords:	Hypertension < CARDIOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PRIMARY CARE, PUBLIC HEALTH

TITLE PAGE

Intervention for control of hypertension in Catalonia, Spain (INCOTECA Project): results of the multicentric non-randomised quasi-experimental controlled intervention study

Authors: R Vallès-Fernández*, T Rodriguez-Blanco, L Mengual-Martínez, M Rosell-Murphy, G Prieto-De Lamot, F Martínez-Frutos, S Mimoso-Moreno, E Bellerino-Serrano, A Àlvarez-Lázaro, A Franzi-Sisó, JC Martínez-Vindel, MS Alonso-Ortega, I Olmedo-Muñoz, JM Bonet-Simó, and the INCOTECA research group.

*Corresponding author:

Name: Dr. Roser Vallès Fernández. Senior pharmacist

Institution: Primary Care Service (SAP) Cerdanyola-Ripollet. Catalan Institute of Health (ICS).

Postal address: CAP Fontetes. Pl. Velázquez s/n. 08291 Cerdanyola del Vallès (Barcelona). Spain

e-mail: rvallesf@gencat.cat

Phone 93 594 21 90.

Fax: 93 580 60 77

Co-authors:

- Teresa Rodríguez- Blanco, statistician. **Institution:** Primary Care Research Institute (IDIAP Jordi Gol). **City:** Barcelona. **Country**: Spain.
- Lucas Mengual-Martínez, general practitioner. **Institution:** Primary Care Team (EAP) Badia del Vallès. Catalan Institute of Health (ICS). **City:** Badia del Vallès. **Country**: Spain.

- Magdalena Rosell-Murphy, epidemiologist and general practitioner. **Institution:** Primary Care Research Institute (IDIAP Jordi Gol). **City:** Barcelona. **Country**: Spain.
- Gemma Prieto-De Lamo, epidemiologist. **Institution:** Primary Care Research Institute (IDIAP Jordi Gol). **City:** Barcelona. **Country**: Spain.
- Fina Martínez-Frutos, general practitioner. **Institution:** Primary Care Team (EAP) Canaletes-Fontetes. Catalan Institute of Health (ICS). **City:** Cerdanyola del Vallès. **Country:** Spain.
- Sonia Mimoso-Moreno, nurse practioner. **Institution:** Primary Care Team (EAP) Canaletes-Fontetes. Catalan Institute of Health (ICS). **City:** Cerdanyola del Vallès. **Country:** Spain.
- Eva Bellerino-Serrano, general practitioner. **Institution:** Primary Care Team (EAP) Ripollet. Catalan Institute of Health (ICS). **City:** Ripollet. **Country:** Spain.
- Alícia Àlvarez-Lázaro, nurse practitioner. **Institution:** Primary Care Team (EAP) Ripollet. Catalan Institute of Health (ICS). **City:** Ripollet. **Country:** Spain.
- Alícia Franzi-Sisó, senior pharmacist. **Institution:** Primary Care Service (SAP) Sabadell-Rubí-St. Cugat-Terrassa. Catalan Institute of Health (ICS). **City:** Sabadell. **Country:** Spain.
- Juan Carlos Martínez-Vindel, general practitioner. **Institution:** Primary Care Team (EAP) Barberà. Catalan Institute of Health (ICS). **City:** Barberà del Vallès. **Country:** Spain.
- Mª Socorro Alonso-Ortega, nurse practitioner. **Institution:** Primary Care Team (EAP) Barberà. Catalan Institute of Health (ICS). **City:** Barberà del Vallès. **Country:** Spain.
- Imma Olmedo-Muñoz, general practitioner. **Institution:** Primary Care Team (EAP) Serraparera. Catalan Institute of Health (ICS). **City:** Cerdanyola del Vallès. **Country:** Spain.

- Josep Mª Bonet-Simó, general practitioner. **Institution:** Primary Care Service (SAP) Cerdanyola-Ripollet. Catalan Institute of Health (ICS). **City:** Cerdanyola del Vallès. **Country:** Spain.

Key words: quality improvement, blood pressure, hypertension, community health.

Word count: 4.098

ABSTRACT

Objective: The purpose of this study was to assess the effectiveness of a Quality Improvement plan aimed at Primary Health Care Teams to optimise hypertension control and to compare it with standard clinical care.

Methods: *Design:* Multicentric non-randomised quasi-experimental controlled intervention study. *Setting:* Five Primary Health Care Teams in the intervention and 13 in the control group in the province of Barcelona, Catalonia, Spain. *Participants:* This is a population-based study in which all patients over 18 years of age with a diagnosis of hypertension before 1 January 2006 were included (n=9,877 in the intervention group and n=21,704 in the control group). *Intervention:* A quality improvement plan that targeted primary care professionals. The plan included training sessions, feedback to health professionals, audit and implementation of recommended clinical practice guidelines for the management of hypertensive patients. *Main outcome measure:* Prevalence of hypertensive patients with an adequate blood pressure control.

Results The adjusted difference between intervention and standard care groups in the odds of blood pressure control was 1.3 (95% confidence interval: 1.1 to 1.6; P=0.003). Results of the mixed model on repeated measures showed that, on average, an individual in the intervention group had an increase of 92% in the odds of blood pressure control (odds ratio: 1.9, 95% confidence interval: 1.7 to 2.1).

Conclusions The implementation of a Quality Improvement plan can improve blood pressure control. This strategy is potentially feasible for up-scaling within the existing primary health care teams.

Trial registration: ClinicalTrials.gov MS: 1998275938244441

ARTICLE SUMMARY

Article focus

- To assess the effectiveness of a QI programme targeting health professionals to optimise BP control in hypertensive patients. Other factors associated with BP control were analysed.

Key messages

- The QI plan aimed at PHCTs (doctors, nurses and administrative staff) implemented in our study has proven effective to improve hypertension control.
- A history of a cardiovascular event has a positive effect in BP control.
- The addition of different antihypertensive drugs to the management of hypertensive patients without considering other aggravating factors does not guarantee a better BP control.

Strengths and limitations of study

- The population-based design and mixed-effects modelling on repeated measures were the main strengths of this study.
- The mixed models approach is a powerful method for analysing data from longitudinal studies which include multiple measurements on each participant
- The most of the intervention in this study has been implemented with few additional resources.
- The duration of the study can be considered the main limitation of this investigation. Longer-term studies that include unmeasured factors are needed to determine the effectiveness and cost-effectiveness of this measure and the impact of a reduction in BP values on cardiovascular morbi-mortality in the hypertensive population.

BACKGROUND

High blood pressure (BP) figures amongst the most common and important health problems in developed countries. Hypertension is an established risk factor for cardiovascular disease, stroke, kidney disease, all cause mortality and shortened life expectancy.[1;2]

The prevalence of hypertension in Spain ranges from 20% to 47% in the population older than 20 years and up to 65% in the population above 60 years of age.[3] It is one of the main reasons for seeking medical attention in primary care, particularly in the elderly population.[3]

One in two cardiovascular deaths in Spanish individuals over 50 is attributable to high blood pressure.[4] A number of studies carried out in Europe and in the United States have shown that BP control in hypertensive patients is suboptimal.[3;5-7]

The Catalan Health Department Health Plan for the 2007-2010 period states that the health systems have to put in place strategies to achieve a 50% control of the hypertensive population.[8]

Inadequate hypertension control has been associated with various factors such as therapeutic compliance, diabetes, age, lifestyle, concomitant treatments, the technique and the equipment to measure BP, etc.[3;6;7;9] Management by primary health care teams (PHCTs) is one of the factors that can influence control of hypertensive patients.[5;10-12] Quality improvement (QI) strategies can target health professionals, patients or both and many QI strategies have focused on improving hypertension control. These interventions can be classified as provider education (materials and instructions given to providers regarding appropriate care for patients), provider reminders (prompts given to providers to perform specific care tasks), provider audit and feedback, patient education, patient reminders, promotion of self-management, team management changes (creation of multidisciplinary teams, addition of new team members, change of roles, case or disease management) and financial regulation and incentives or reimbursement changes.[12]

Previous studies have shown the positive impact of multifaceted QI interventions on BP control. However, few of these studies have been analysed using the appropriate methodology or have been designed as population based. We believe therefore that the evaluation of the effectiveness of a programme to improve health care quality targeting primary health care professionals with the aim to optimise BP control in the whole hypertensive population is warranted. [5;10-12]

We had hypothesized that a plan for QI at primary health care level addressed to primary health care professionals would improve the management and control of hypertensive patients. Our primary aim was to assess the effectiveness of a QI programme targeting health professionals to optimise BP control in hypertensive patients. Other factors associated with BP control were analysed.

METHODS

The study protocol received institutional review board approval (IDIAP Jordi Gol Ethical Clinical Committee) and it conforms to the principles embodied in the Declaration of Helsinki. The detailed methods and the study protocol have been described elsewhere.[13]

Recruitment and assignment

The study took place from January 2006 to April 2008. All hypertensive patients diagnosed and registered in the electronic clinical records (ECRs) of 18 PHCTs (405,232 inhabitants) in the Barcelona province (Catalonia, Spain) were included in this population-based study. All the Catalan Institute of Health PHCTs invited to take part in this study accepted.

Inclusion criteria: patients eligible to be enrolled in the study were over 18 years of age and with a hypertension diagnosis before 1 January 2006. A diagnosis of hypertension was considered when the doctor had entered in the patient's clinical record the relevant ICD-10 code (code: I10), following the recommendations of the European Hypertension Guidelines.[14]

Exclusion criteria: we excluded patients without electronic clinical measurements in the year previous to the study.

The non-random allocation to the control or intervention groups was decided on the basis of the administrative area. Each PHCTs administrative area has its own training and tasks strategies. The study design was therefore not randomised by PHCT to reduce the possibility of contamination between the PHCTs of the same administrative area.

The intervention group consisted of 5 PHCTs in the Cerdanyola-Ripollet area with a catchment population of 135,505 at the onset of the study. The standard care group (control group) consisted of 13 PHCTs in the Sabadell area with a catchment population of 269,727 inhabitants. Both primary health care areas are comparable in terms of population characteristics and socio-economic level. The study was fully explained to health professionals in both the standard and intervention groups and verbal consent to participate was obtained.

Quality-Improvement intervention

The study intervention consisted in the implementation of a QI plan targeted at all health professionals (approximately 430 between physicians, nurses and administrative staff) working in PHCTs in the Cerdanyola-Ripollet administrative area. In the Sabadell administrative area, the number of professionals was approximately 600. Briefly, the QI plan was divided in four phases:

1) Pre-intervention: non-validated BP monitors were removed from the PHCTs examination rooms and replaced by the digital OMRON M6 BP monitor.[15] The blood pressure measurement technique was standardized in both groups following the Clinical Practice Guidelines recommendations.[14;16]

   The software used to store computerised clinical records was modified for health professionals to be able to enter specific data related to hypertensive patients following the Catalan Institute of Health guidelines on hypertension.[16]

2) Second phase (intervention group): a programme was designed to train PHCTs' doctors and nurses. Posters and leaflets with specific educational contents were made

available to participants. A total of 8 workshops at each of the participating PHCTs took place in three stages (mean attendance rate at workshops was 65% with 6,59 mean assessment points over ten points range):

-Year 2006: three sessions to introduce the QI plan, revise the criteria for diagnosis of hypertension, BP measurement method and criteria for entering data in the computerised clinical record.

-Year 2006-2007: three sessions to discuss issues such as the implementation of the QI plan, hypertension treatment and approach to poor compliance.

-Year 2008: two sessions to present the interim results of the QI plan and the comprehensive management of hypertensive patients.

3) Third phase (intervention group): from April 2007 to April 2008 the interventions focused on the identification of patients with uncontrolled hypertension and the improvement of their management. The applied measures were: six-monthly feedback to professionals; audits to evaluate the implementation of the QI plan; and a reference team (a doctor and a nurse) assigned to every PHCT.
4) Fourth phase: evaluation of the effectiveness of a QI plan

Professionals allocated to the standard care group followed the standard clinical management based on the Catalan Institute of Health hypertension guidelines.[16]

Masking

The study was not blinded at PHCT or patient level because of the nature of the intervention. The analyst was unaware of the group allocation.

Data collection

Primary care professionals enter the results and activities of their work in the e-CAP database regularly. The data collection procedure involved the reading of this computerised clinical records database approximately every 4 months from April 2007 to April 2008.

Outcomes and other variables

Control of hypertension based on the average SBP and DBP reading records over the last 12 months was considered a dichotomous outcome variable (yes/no). The median number of BP readings was three (interquartile range: two to five). SBP and DBP were evaluated as dependent continuous variables.

BP control was defined as SBP < 140 mmHg and DBP < 90 mmHg. In patients with diabetes, heart or renal failure, control values were defined as SBP < 130 mmHg and DBP < 85 mmHg. Other variables considered were: age (continuous); sex (male/female); number of antihypertensive drugs as categorical (0 / 1/ 2 / 3 or more drugs); comorbidities as presence of diabetes mellitus type I or II, heart failure or renal failure (yes /no); cardiovascular events as presence of acute myocardial infarction, angina or stroke (yes/no).

Analysis

Data were reported according to the standard published by the TREND group.[17] Descriptive statistics were used to describe the study population.

Differences between groups at baseline and at follow-up times were assessed by comparing means, medians or percentages, depending on the type of variable.

The analysis was performed at individual level using methods for clustered data (grouping factor: PHCT) [18] and based on the intention-to-treat principle.

The following time points were considered for data collection: baseline, four, nine and 12 months. Patients were included in the analysis if data were available for at least one follow-up time point in addition to the baseline data. To address potential biases due to incomplete follow-up data, we imputed missing values using the last known value carried forward.

The intervention effect was assessed through observed change and standardised effect-size (SES).[19-21] For between-group comparisons, SES were calculated following Kazis' et al method.[20]

For within-group comparisons the longitudinal form of SES, also known as the standardised response mean (SRM), was used.[19;20;22] Cohen's rule of thumb for interpreting the effect size

index, a value of 0.2 as small, 0.5 as moderate, and 0.8 or greater as large, can be applied to the SRM.[19]

Linear and logistic mixed-effects models with PHCT as random effect were used to allow for within-PHCT correlation to assess the effect of the intervention at 1-year follow-up, adjusted for baseline measurement and for differences between groups in the individual variables. The odds ratio (OR) for the logistic model was estimated as the exponential function of the regression coefficient, exp (coefficient).

The individual variables considered were age, sex, number of antihypertensive drugs, comorbidity and cardiovascular event.

We examined the effects of intervention over all time points using mixed-effects models on repeated measures.[23;24] Level-1 covariates varied by measurement occasion and included time (age-centred at 1-year follow-up), number of antihypertensive drugs, comorbidity and cardiovascular event. Level-2 covariates varied by subject and included sex and group. Interactions between time and group effect were assessed.

All models have been compared by the partial likelihood ratio test and Akaike's information criterion (AIC). All results are shown with their 95% confidence intervals (CI). Statistical significance was set at P<0.01 (two-tailed).

Stata SE 11.0 (StataCorp LP, College Station, Texas), and SAS statistical software version 9.1 (SAS Institute Inc, Cary, North Carolina) were used for all analyses.

RESULTS

A total of 51,642 people were included in the study, 16,422 (5 PHCTs) were allocated to the intervention and 35,220 (13 PHCTs) to the standard care group. The exclusion rate was 33.5% (17,315 patients). Follow-up data were available for 92% of the patients. The final analysis included 31,581 patients, 9,877 (5 PHCTs) in the intervention arm and 21,704 (18 PHCTs) in the standard care arm (Figure 1).

The mean age of the standard care group was slightly higher and presented a higher proportion of cardiovascular events than the patients in the intervention group. Otherwise the groups were clinically comparable (Table 1).

Table 1: Patient characteristics.

	Total	Standard care group	Intervention group	P-value*
No PHCTs	18	13	5	
No of patients	31581	21704	9877	
Demographic/clinical variables				
Age, years (mean [SD])	68.6 (11.6)	69.1 (11.5)	67.6 (11.6)	<0.001
Sex,female	18825 (59.6)	12914 (59.5)	5911 (58.8)	0.562
No of BP drugs,(mean [SD]; median [IQR])	1.4[0.8];1(1-2)	1.4 [0.9]; 1(1 to 2)	1.5 [0.9]; 1(1 to 2)	0.028**
Patients with antyhypertensive drugs n (%)				
0	3315 (10.5)	2319 (10.7)	996 (10.1)	0.031
1	15209 (48.1)	10501 (48.4)	4708 (47.7)	
2	9068 (28.7)	6212 (28.6)	2856 (28.9)	
3 or more	3989 (12.6)	2672 (12.3)	1317(13.3)	
Comorbidity#	9490 (30.0)	6584 (30.3)	2906 (29.4)	0.101
Diabetes mellitus	8309 (26.3)	5720 (26.3)	2589 (26.2)	0.79
Renal failure	1022 (3.2)	721 (3.3)	301 (3.1)	0.201
Heart failure	862 (2.7)	648 (2.9)	214 (2.2)	<0.001
CV event&	3839 (12.2)	2928 (13.5)	911 (9.2)	<0.001
Outcome characteristics $				
BP control	14195 (44.9)	9854 (45.4)	4341 (43.9)	0.016
SBP, mmHg (mean [SD])	138.3 (13.6)	138.1 (13.6)	138.7 (13.7)	<0.001
DBP, mmHg (mean [SD])	79.5 (8.5)	79.4 (8.3)	79.5 (8.9)	0.231

Abbreviations: PHCTs=Primary Health Care Teams; BP= blood pressure; CV= cardiovascular; SBP= systolic blood pressure; DBP= diastolic blood pressure; IQR=interquartile range

* P-values were calculated from a Student's t-test, the chi-square test or medians' test as appropriate, by comparing the different intervention groups

** P-value for median comparison

Comorbidity: presence of diabetes mellitus type I or II, heart failure or renal failure;

$ Blood pressure was calculated from the mean of 3.5 (SD: 2.2) (median (IQR: 3[2, 5])) blood pressure readings obtained during one year

& CV =cardiovascular events: patient's clinical history of ICD-10 codes of acute myocardial infarction, angina or stroke

Hypertension was defined as SBP >= 140 mmHg and DBP >= 90 mmHg of clinical blood pressure measurements. In patients with diabetes, heart or renal failure (code ICD-10: E10 –E11- N17 – N18- N19- I50), hypertension were defined as SBP >= 130 mmHg and DBP >= 85 mmHg.

BP control was defined as SBP < 140 mmHg and DBP < 90 mmHg. In patients with diabetes, heart or renal failure, control values were defined as SBP < 130 mmHg and DBP < 85 mmHg.

A faster increase in the percentage of BP control was observed in the intervention group during the follow-up period. In the intervention group BP was 1.3 times more likely to be controlled than in the standard care group (adjusted OR: 1.3, 95% CI 1.1 to 1.6; P=0.003) (Table 2).

Table 2: Changes in BP control, SBP and DBP within and between intervention and standard care group with missing data replaced using last value carried forward.

	Standard care group (n=21704)			Intervention group (n=9877)			Difference (95% CI) between groups (intervention group−control group)				
	n (%) or mean (SD)	Difference* (95% CI)	SRM#	n (%) or mean (SD)	Difference* (95% CI)	SRM#	Unadjusted difference	P-value	SES$	Adjusted difference**	P-value
BP control											
baseline	9854 (45.4)			4341 (43.9)							
four months	9657 (44.5)	-0.9 (-1.5 to -0.3)		4547 (46.0)	2.1 (1.2 to 2.9)		1.5 (0.4 to 2.7)	0.011			
nine months	9469 (43.6)	-1.8 (-2.4 to -1.2)		4614 (46.7)	2.8 (1.9 to 3.6)		3.1 (1.9 to 4.3)	<0.001			
1-year	9457 (43.6)	-1.8 (-2.5 to -1.1)		4880 (49.4)	5.5 (4.4 to 6.5)		5.8 (4.6 to 7.0)	<0.001		1.3 (1.1 to 1.6)£	0.003
SBP (mmHg)											
baseline	138.1 (13.6)			138.7 (13.7)							
four months	138.3 (13.6)	0.3 (0.1 to 0.4)	-0.03	138.3 (13.7)	-0.4(-0.5 to -0.2)	0.04	0.0 (-0.3 to 0.3)	0.95	0.00		
nine months	138.5 (13.1)	0.4 (0.3 to.0.5)	-0.04	137.9 (13.1)	-0.8 (-1.0 to -0.6)	0.09	-0.6 (-0.9 to -0.3)	<0.001	0.05		
1-year	138.6 (13.8)	0.5 (0.3 to 0.7)	-0.04	136.7 (13.3)	-2.0 (-2.3 to -1.8)	0.16	-1.9 (-2.2 to -1.6)	<0.001	0.14	-2.1(-3.3 to -0.8)	0.001
DBP (mmHg)											
baseline	79.4 (8.3)			79.5 (8.9)							
four months	78.9 (8.3)	-0.4 (- 0.5 to -0.4)	0.07	78.7 (9.0)	-0.8 (-0.9 to -0.7)	0.14	-0.2 (-0.4 to -0.0)	0.023	0.03		
nine months	78.0 (8.1)	-0.4 (-0.5 to -0.3)	0.07	78.6 (8.7)	-0.9 (-1.0 to -0.8)	0.15	-0.4 (-0.6 to -0.2)	<0.001	0.05		
1-year	78.6 (8.5)	-0.7 (-0.8 to -0.6)	0.09	77.9 (9.0)	-1.6 (-1.7 to -1.4)	0.21	-0.7 (-0.9 to -0.5)	<0.001	0.08	-0.9(-1.3 to -0.5)	<0.001

Abbreviations: PHCT=Primary Health Care Team; BP= blood pressure; CV= cardiovascular; SBP= systolic blood pressure; DBP= diastolic blood pressure; SD= standard deviation; CI= confidence interval

*Mean differences are shown for quantitative outcomes and percentage differences for dichotomous outcomes Differences were calculated between follow-up measurements and baseline measurements.

SRM: Standardized response mean was calculated as the mean change by the standard deviation of the change

$ SES: Standardised effect size was calculated as the mean difference between intervention and control groups divided by the standard deviation of the control measurement.

A positive SRM or SES denotes improvement; a negative one denotes worsening of some clinical measurements

**Estimated with a mixed-effects model considering PHCT as random effect. Mean differences are shown for quantitative outcomes and odds ratios for dichotomous outcomes.

Adjusted for age at baseline; sex; number of antihypertensive drugs; comorbidity; cardiovascular event and baseline measurement.

£ Value is odds ratio (95%CI)

The mean differences and SRM for within-groups comparisons of SBP and DBP were larger in the intervention group than in the standard care group. A larger mean difference and SRM were detected in SBP and DBP at 1 year follow-up, with slightly higher values for DBP. According to the Cohen's guidelines,[19] only this change in DBP can be considered a relevant change, though it represents a small effect size (SRM=0.21).

The larger significant differences between intervention and standard care group were found at 1 year follow-up in favour of the intervention for SBP and DBP. However, the SES did not reach a small effect.

In the repeated measures analysis, the proportion of patients who maintained BP control during follow-up was 38.4% (95% CI 38.1 to 38.7) (intervention group: 40%, 95% CI 39.4 to 40.5; standard care group: 37.7% , 95% CI 37.3 to 38.1) and the proportion of patients that improved over time (to pass to BP control) was 6.6% (95% CI 6.4 to 6.7) (intervention group: 7.4% , 95% CI 7.1 to 7.7; standard care group: 6.2%, 95% CI 6 to 6.4). The difference in percentage in patients who maintained BP control between intervention and standard care group was 2.3% (95% CI 1.6 to 2.3) and the difference in those who improved was 1.2% (95% CI 0.8 to 1.5). The global trend showed a highly significant change in BP control over time (P<0.001).

In the multilevel analysis we found that after 1 year follow-up an individual in the intervention group was expected on average to have an increase of 92% (OR: exp [0.65] =1.9, 95% CI 1.7 to 2.1) in the odds of BP control, a reduction of 1.77 mmHg on the SBP (95% CI -2.10 to -1.45) and of 0.78 mmHg in DBP (95% CI -0.98 to -0.57). The effect of time showed that a patient in the intervention group experienced an increase in BP control together with a reduction in SBP and DBP over time. (Table 3)

Table 3. Effects of covariates on Blood Pressure control, Systolic and Diastolic Blood Pressure (N=31581). Mixed-effects models on repeated measures (phases 1-4).

			Blood Pressure control [#]			Systolic Blood Pressure [&]			Diastolic Blood Pressure [&]		
			Adjusted ß	SE	P-value	Adjusted ß	SE	P-value	Adjusted ß	SE	P-value
Fixed effects											
Final status	Intercept		0.54	0.05	<.0001	137.93	0.14	<.0001	80.01	0.09	<.0001
	Group (ref. control)		0.65	0.06	<.0001	−1.77	0.17	<.0001	−0.78	0.10	<.0001
	Gender (ref. male)		0.14	0.05	0.006	−0.11	0.14	0.434	−0.60	0.09	<.0001
	Number of antihypertensive drugs (ref. 1 drug)										
		0 drugs	0.16	0.08	0.049	−0.53	0.18	0.004	0.01	0.11	0.898
		2 drugs	−0.44	0.05	<.0001	0.89	0.12	<.0001	−0.31	0.08	<.0001
		>=3 drugs	−0.69	0.07	<.0001	1.49	0.17	<.0001	−0.79	0.10	<.0001
	Comorbidity (ref. No)		−3.92	0.06	<.0001	1.49	0.13	<.0001	−1.42	0.08	<.0001
	Cardiovascular event (ref. No)		0.51	0.06	<.0001	−1.05	0.16	<.0001	−2.01	0.10	<.0001
Rate of change											
	Time		−0.21	0.04	<.0001	0.93	0.11	<.0001	−0.29	0.07	<.0001
	Time*Group		0.80	0.06	<.0001	−2.51	0.15	<.0001	−0.78	0.09	<.0001
	Time*Number of antihypertensive drugs (ref. 1 drug)					−1.58			−1.07		
		0 drugs	−0.12	0.10	0.217	0.30	0.24	0.206	0.31	0.14	0.282
		2 drugs	0.26	0.06	<.0001	−0.92	0.16	<.0001	−0.52	0.09	<.0001
		>=3 drugs	0.34	0.09	<.0001	−2.09	0.21	<.0001	−1.04	0.12	<.0001
Random effects			Variance	SE		Variance	SE		Variance	SE	
Level1	Within-person (Residual)					26.65	0.15	<.0001	9.65	0.05	<.0001
Level2	In final status (intercept)		12.64	0.24	<.0001	165.83	1.48	<.0001	67.20	0.59	<.0001
	In rate of change (Time)					104.35	1.26	<.0001	36.14	0.44	<.0001
	Covariance					53.74	1.06	<.0001	20.30	0.40	<.0001
Goodness of fit											
	Deviance		115503			906066.8			780098.3		
	AIC		115531			906100.8			780132.3		
	BIC		115648			906243.0			780274.4		

Note: Time was patient's age centred at 1-year follow-up (Final status); ref.= Reference; SE= Standard Error; AIC= Akaike's Bayesian Information Criterion; BIC= Bayesian Information Criterion

[#]: SAS Proc Nlmixed; & SAS Proc mixed, full ML

Another associated factor which increased the probability of BP control was a cardiovascular event, also significantly associated with a reduction in SBP and DBP. Furthermore, the presence of comorbidity was associated with lower DBP but with a worse BP control and higher SBP. The use of two or more antihypertensive drugs was associated with a significant decreased BP control and higher SBP, but lower DBP. In all three models, there was strong

evidence of variation in the outcomes between participants, as indicated by the random intercepts. (Table 3)

DISCUSSION

Principal findings of the study

Our results show a significant improvement in the intervention compared with the standard care group consistent across all assessed outcomes. The different models used to analyse the data from our study indicate that the implementation of a QI plan is effective in increasing BP control and decreasing both SBP and DBP. The analysis adjusted by baseline data shows that patients in the intervention group had 30% more probability of an adequate BP control after 1 year follow-up. In the intervention group, mean SBP and DBP values decreased 2.1 mmHg and 0.9 mmHg, respectively, compared with the patients from the standard care group.

The patients in the intervention group had a higher probability of an adequate BP control (OR: 1.9), as shown by the repeated measures analysis. The percentage of patients that maintained a good BP control or that changed from poor to adequate BP control was larger in the intervention (2.3%) than in the standard care group (1.2%).

Comparison with other studies

Various reviews and meta-analyses on the effectiveness of QI strategies to improve BP control have been published.[5;10-12] In general, QI interventions on BP control are considered effective, although the results are variable and difficult to compare. For instance, the change in SBP and DBP values in QI interventions that included monitoring and feedback for providers was 1.5/0.6 mmHg,[12] a result similar to the current study. There is a recently study too which evaluated the effectiveness of a continuing medical education program to train primary care providers in evidence-based guidelines for hypertension prevention and control. [25] The change in BP was 1,99 mmHg in SBP and 1,49 mmHg in DBP. This intervention was cost-effective strategy to address hypertension.[26] The study reported by Landon and

colleagues was carried out in asthmatic and diabetic patients.[27] Despite the lack of differences amongst groups, in the hypertension subgroup the percentage of adequate control was similar to ours.

Effectiveness varies according to the study. BP control and reduction in SBP and DBP values are analysed in two studies in relation to the type of intervention carried out: either a qualitative intervention aimed at general practitioners very similar to our study or an educational intervention aimed at patients.[28;29] The results related to the general practitioners differed from the results of our investigation. Effectiveness was evaluated after two years and no improvement in BP control was observed. However, they obtained a more significant reduction in SBP and DBP values (5 and 4 mmHg, respectively)**.** This could be explained by their very low levels of BP control (27.8%) at the onset of the study, their very high SBP and DBP means (153.3 mmHg and 92.9 mmHg, respectively), and the health infrastructure of a developing country (Pakistan). Therefore, even if SBP and DBP values improved significantly, BP control was below the target of the Blood Pressure control Clinical Practice Guidelines.[28]

In the 6-month study, SBP reduction was 0.3 mmHg (95% CI -1.5 to 2.2; P=0.76). [29] The following reasons may account for this lack of effect: (1) the intervention was addressed only to physicians; (2) the analysis was based on the patients that had completed follow-up; (3) and the study population represented a relatively healthy cohort with high rates of BP control at baseline.

On the other hand, a study similar to ours published by Gomez and colleagues[30] with the aim to reduce cardiovascular risk in hypertensive patients showed that the differences between the intervention and control groups in SBP and DBP values were larger, -9.0 mmHg (95% CI -11.3 to -6.7) and -3.9 mmHg (95% CI -5.4 to -2.4), respectively. The greater reduction of BP values in this study compared to ours could be explained by the recruitment of only 849 hypertensive patients with a long-term regular follow up in the PHCTs, instead of the whole

hypertensive population included in our study. Such studies allow health professionals to focus on the follow-up of these patients to achieve better results, but lower patient numbers limit their external validity. The impact of a previous cardiovascular event on BP control in these studies is not known. [27-30]

Despite the small impact of our intervention on SBP and DBP, we consider these results clinically relevant since several studies show that small reductions in SBP and DBP in the general population are associated with a decrease in the number of cardiovascular events: a 10% reduction in stroke mortality and around 7% reduction in mortality due to cardiovascular disease in the middle-aged population have been associated to a 2 mmHg decrease in SBP. [31;32]

It is important to emphasise that other factors that influence poor BP control are the presence of comorbidities and treatment with two or more antihypertensive drugs. Following the recommendations in the clinical guidelines, it is sometimes necessary to increase the number of drugs to improve BP control.[14;16;33;34] Moreover, unknown or unmeasured confounding factors not analysed in this study, such as patient's treatment compliance, could explain the fact that this association has not been found in our study.

Strengths and weaknesses of the study

The population-based design and mixed-effects modelling on repeated measures were the main strengths of this study. The extensive catchment population included in the investigation reinforces the external validity of these findings. Most studies on similar QI strategies have been carried out in samples of hypertensive patients.[27-29;35]

The mixed models approach is a powerful method for analysing data from longitudinal studies which include multiple measurements on each participant.[24;36] This approach allows the use of all available data and explicit modelling of the within- and between-person variation in the outcome, while taking into account the correlation between measurements obtained from the same individual, which other classical models of analysis cannot explore.

We would like to emphasise that most of the intervention in this study has been implemented with few additional resources, since the QI plan was carried out with the usual human and financial resources allocated to the health area of the intervention group. Only the publication of the training material in the form of posters and leaflets and the replacement of sphygmomanometers involved additional costs. Sometimes, the main difficulty lies in the feasibility of including in the PHCT routine and at low cost simultaneous strategies that impact on every hypertensive patient.

The duration of the study can be considered the main limitation of this investigation. We have not been able to determine if the improvements are sustainable after the intervention was finalised, though a study carried out in Spain suggested that the effect of quality interventions on hypertension tend to decrease over time.[30] Also, we do not know if a better hypertension control in the intervention group is related to a decrease in cardiovascular morbi-mortality.

The impossibility of randomising by PHCT is another limitation of the study, partially compensated by selecting two different administrative health areas for each group to prevent contamination issues amongst PHCT professionals of the same area.

The BP measurements used in the study were obtained as part of the routine care and were therefore subjected to error and variability amongst professionals, as reflected in the computerised clinical record. To minimise variability, training workshops took place during the one year follow-up on BP measurement methods and data entry in the patient's clinical record.

Policy implications, future research and conclusions

The results of this study show that in our setting it is feasible to implement a QI plan for the improvement of hypertension control in the PHCTs. The design of this QI plan to integrate it in the regular clinical care of the PHCT professionals (doctors, nurses and administrative staff) without a significant increase in workload or cost is its main advantage. Longer-term studies that include unmeasured factors are needed to determine the effectiveness and cost-

effectiveness of this measure and the impact of a reduction in BP values on cardiovascular morbi-mortality in the hypertensive population.

Acknowledgements: This study has been possible thanks to the generous collaboration of doctors and nurses from the Cerdanyola-Ripollet Primary Care Area (ICS), which constitutes the INCOTECA Research Group. We are also indebted to the computing and infrastructure staff at the Àmbit Centre of the Catalan Health Institute and to Javier Sevilla in particular. Thanks for Eulàlia Farré to translate the paper.

Competing interests: None declared.

Funding statement: In 2006 the project received the Research Prize in Primary Health Care of the Catalan Health Service Barcelona Region. In 2006 the project obtained an award to the Best Initiatives in Pharmaceutical Attention, published in the *Correo Farmacéutico*. Esteve Laboratories funded the production of posters and leaflets with the decision-making algorithms. IDIAP Jordi Gol funded the translation of the paper from Spanish into English.

Contributors: RVF contributed to conception and design of study and analysis and interpretation of data, and drafting and revising of the article, and gave final approval. TRB and MRM contributed to analysis and interpretation of data and drafting and revising of article and gave final approval. MRM, LMM, GMDL and AFS contributed to conception and design of study. LMM, FMF, SMM, EBS, AAL, JCMV, MSAO and IOM contributed to acquisition of data. JMBS contributed to drafting and revising of the article.

Other contributor who do not qualify as authors:

The INCOTECA Research Group:, Núria Aznar (EAP Barberà, ICS); Ana Mª Cascos, (EAP Serraparera, ICS); Olga Correcher (SAP Cerdanyola-Ripollet, ICS); Guadalupe Figueiras, (SAP Cerdanyola-Ripollet, ICS); Consol Heras, (DAP Metropolitana Nord, ICS); Òscar Hernández, (SAP Sabadell-Rubí-St.Cugat-Terrassa); Sebastià Juncosa, (DAP Metropolitana Nord, ICS); Fernando Marín, (Centre Corporatiu, ICS); Carmen Martínez,

(DAP Metropolitana Nord, ICS); Jordi Puig (SAP Bages-Berguedà); Carolina Rovira, (SAP Bages-Berguedà); Javier Sevilla (DAP Metropolitana Nord, ICS); Joaquim Verdaguer, (DAP Metropolitana Nord, ICS).

Ethical approval: The study protocol has received institutional review board approval (IDIAP Jordi Gol Ethical Clinical Committee).

Data sharing statement: No additional data available

REFERENCES

Reference List

(1) Lopez AD, Mathers CD, Ezzati M, *et al.*. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* 2006;367:1747-1757.

(2) Kearney PM, Whelton M, Reynolds K, *et al*. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005;365:217-223.

(3) Rodriguez Roca GC, Artigao Rodenas LM, Llisterri Caro JL, *et al*. [Control of hypertension in elderly patients receiving primary care in Spain]. *Rev Esp Cardiol* 2005;58:359-366.

(4) Graciani A, Zuluaga-Zuluaga MC, Banegas JR, *et al*. [Cardiovascular mortality attributable to high blood pressure in Spanish population over 50]. *Med Clin (Barc)* 2008;131:125-129.

(5) Glynn LG, Murphy AW, Smith SM, *et al*. Interventions used to improve control of blood pressure in patients with hypertension. *Cochrane Database Syst Rev* 2010; 3:CD005182.

(6) Kaplan NM, Opie LH. Controversies in hypertension. *Lancet* 2006;367:168-176.

(7) Llisterri Caro JL, Rodriguez Roca GC, Alonso Moreno FJ, *et al.* [Control of blood pressure in Spanish hypertensive population attended in primary health-care. PRESCAP 2006 Study]. *Med Clin (Barc)* 2008;130:681-687.

(8) Departament de Sanitat i Seguretat Social. Pla de salut de Catalunya a l'horitzó 2010. Informe de Salut a Catalunya [2010 Available from: URL:http://www20.gencat.cat/portal/site/pla-salut/menuitem.7baf2c730ce9e94d061ead10b0c0e1a0/?vgnextoid=f2a810b73ed17110VgnVCM1000000b0c1e0aRCRD&vgnextchannel=f2a810b73ed17110VgnVCM1000000b0c1e0aRCRD&vgnextfmt=default

(9) Rodriguez-Roca GC, Pallares-Carratala V, Alonso-Moreno FJ, *et al.* Blood pressure control and physicians' therapeutic behavior in a very elderly Spanish hypertensive population. *Hypertens Res* 2009;32:753-758.

(10) Carter BL, Rogers M, Daly J, *et al*. The potency of team-based care interventions for hypertension: a meta-analysis. *Arch Intern Med* 2009;169:1748-1755.

(11) Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. *Br J Gen Pract* 2005;55:875-882.

(12) Walsh JM, McDonald KM, Shojania KG, *et al*. Quality improvement strategies for hypertension management: a systematic review. *Med Care* 2006;44:646-657.

(13) Valles-Fernandez R, Rosell-Murphy M, Correcher-Aventin O, *et al*. A quality improvement plan for hypertension control: the INCOTECA Project (INterventions for COntrol of hyperTEnsion in CAtalonia). *BMC Public Health* 2009;9:89.

(14) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* 2003;21:1011-1053.

(15) Topouchian JA, El Assaad MA, Orobinskaia LV, *et al*. Validation of two automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension: the Omron M6 (HEM-7001-E) and the Omron R7 (HEM 637-IT). *Blood Press Monit* 2006;11:165-171.

(16) Amado E, Brotons C, Dalfó A, *et al*. Guia de Práctica Clínica Hipertensió Arterial. Guies de Pràctica Clínia i Material Docent [2003 6 Available from: URL:http://www.gencat.net/ics/professionals/guies/hipertensio/hipertensio.htm

(17) Des J, Lyles C, Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. *Am J Public Health* 2004;94:361-366.

(18) Ukoumunne OC, Gulliford MC, Chinn S, *et al*. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. *Health Technol Assess* 1999;3:iii-92.

(19) Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Associates, New Jersey: LE Associates; 1988.

(20) Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. *Med Care* 1989;27(3 Suppl):S178-S189.

(21) Terwee CB, Dekker FW, Wiersinga WM, *et al*. On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. *Qual Life Res* 2003;12:349-362.

(22) Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. *Med Care* 2004;42:851-859.

(23) Burton P, Gurrin L, Sly P. Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-level mixed modelling. *Stat Med* 1998;17:1261-1291.

(24) Singer J, Willett J. Applied longitudinal data analysis: modelling change and event occurrence. New York: Oxford University Press; 2003.

(25) Allaire BT, Trogdon JG, Egan BM, *et al*. Measuring the impact of a continuing medical education program on patient blood pressure. *J Clin Hypertens (Greenwich)* 2011;13:517-522.

(26) Trogdon JG, Allaire BT, Egan BM, *et al*. Training providers in hypertension guidelines: Cost-effectiveness evaluation of a continuing medical education program in South Carolina. *Am Heart J* 2011;162:786-793.

(27) Landon BE, Hicks LS, O'Malley AJ, *et al*. Improving the management of chronic disease at community health centers. *N Engl J Med* 2007;356:921-934.

(28) Jafar TH, Hatcher J, Poulter N, *et al.* Community-based interventions to promote blood pressure control in a developing country: a cluster randomized trial. *Ann Intern Med* 2009;151:593-601.

(29) Svetkey LP, Pollak KI, Yancy WS, *et al*. Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients. *Hypertension* 2009;54:1226-1233.

(30) Gomez Marcos MA, Rodriguez SE, Ramos DE, *et al*. [Durability of the effects of a quality improvement intervention in hypertensive patients on long-term follow-up (CICLO-RISK study)]. *Aten Primaria* 2009;41:371-378.

(31) Cook NR, Cohen J, Hebert PR, *et al*. Implications of small reductions in diastolic blood pressure for primary prevention. *Arch Intern Med* 1995;155:701-709.

(32) Lewington S, Clarke R, Qizilbash N, *et al*. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002;360:1903-1913.

(33) Boger-Megiddo I, Heckbert SR, Weiss NS, *et al*. Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. *BMJ* 2010;340:c103.

(34) Mancia G, De BG, Dominiczak A, *et al*. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. *J Hypertens* 2007;25:1751-1762.

(35) Gomez Marcos MA, Garcia OL, Gonzalez Elena LJ, *et al*. [Effectiveness of an intervention to improve quality care in reducing cardiovascular risk in hypertense patients]. *Aten Primaria* 2006;37:498-503.

(36) Goldstein H, Browne W, Rasbash J. Multilevel modelling of medical data. Stat Med 2002;21:3291-3315.



Fig 1 Flow chart of study. PHCT= Primary Health Care Teams; BP= blood pressure

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*

Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	1
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	4,5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	7-8
Objectives	3	State specific objectives, including any pre-specified hypotheses	8
Methods			
Study design	4	Present key elements of study design early in the paper	8-12
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-9
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	8-9
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	*10*
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	11,12
		(*b*) Describe any methods used to examine subgroups and interactions	11,12
		(*c*) Explain how missing data were addressed	11
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed	

		Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	
		(*e*) Describe any sensitivity analyses	11,12
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12,13
		(b) Give reasons for non-participation at each stage	12
		(c) Consider use of a flow diagram	12 (figure 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13 (table 1)
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events or summary measures	13 (table 1)
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14,15,16
		(*b*) Report category boundaries when continuous variables were categorized	13 (table 1)
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	14,16 (table 2 and 3)
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15,16 (table 3)
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19,20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-20
Generalisability	21	Discuss the generalisability (external validity) of the study results	20,21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.